Daiichi Sankyo Launches Once-Daily LIXIANA? Sales Alliance in Europe

Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter,
Daiichi Sankyo) today announced that its European subsidiary, Daiichi
Sankyo Europe GmbH Group (headquartered in Munich, Germany;
hereafter, DSE), has granted exclusive rights to Merck & Co, Inc.,
Kenilworth, NJ, USA (NYSE: MRK), known as MSD outside the US and
Canada (hereafter, MSD) to market the oral, once-daily
anti-coagulant, LIXIANA® (edoxaban), in 13 European countries:
Bulgaria, Croatia, Czech Republic, Denmark, Finland, Hungary,
Iceland, Norway, Poland, Romania, Slovakia, Slovenia and Sweden. DSE
currently has no affiliated companies in these countries, so this
agreement will contribute significantly to the growth of edoxaban in
Europe.

The aforementioned 13 countries are subject to the marketing
authorization of the oral, once-daily anti-coagulant edoxaban which
was obtained from the European Commission last June. Sales will
proceed as soon as MSD completes launch preparations.

"Following the successful launches of the oral, once-daily edoxaban
by Daiichi Sankyo in a number of European markets, we are extremely
happy about the agreement with MSD which makes edoxaban now also
accessible to patients in Northern and Central Eastern Europe", says
Jan Van Ruymbeke, CEO Daiichi Sankyo Europe, "and we believe having
one of the biggest pharma companies in the world as our partner is a
vote of confidence in edoxaban's potential in the NOAC market."

About Edoxaban

Edoxaban is an oral, once-daily, direct factor Xa (pronounced "Ten
A") inhibitor. Factor Xa is one of the key components responsible for
blood clotting, so inhibiting this makes the blood thin and less
prone to clotting.

Edoxaban received EU approval in June 2015 for the prevention of
stroke and SE in adult patients with NVAF with one or more risk
factors, such as congestive heart failure, hypertension, age >= 75
years, diabetes mellitus, prior stroke or transient ischaemic attack
(TIA), as well as for the treatment of deep vein thrombosis (DVT) and
pulmonary embolism (PE), and prevention of recurrent DVT and PE in
adults. Edoxaban is currently marketed in the UK, Germany, the
Netherlands, Ireland, Switzerland, the US and Japan. In other
countries, regulatory review is ongoing.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of
innovative pharmaceutical products to address diversified, unmet
medical needs of patients in both mature and emerging markets. With
over 100 years of scientific expertise and a presence in more than 20
countries, Daiichi Sankyo and its 17,000 employees around the world
draw upon a rich legacy of innovation and a robust pipeline of
promising new medicines to help people. In addition to its strong
portfolio of medicines for hypertension, dyslipidemia, bacterial
infections, and thrombotic disorders, the Group's research and
development is focused on bringing forth novel therapies in
cardiovascular-metabolic diseases, pain management, and oncology,
including biologics. For more information, please visit:
http://www.daiichi-sankyo.eu.

Forward-looking statements

This press release contains forward-looking statements and
information about future developments in the sector, and the legal
and business conditions of DAIICHI SANKYO Co., Ltd. Such
forward-looking statements are uncertain and are subject at all times
to the risks of change, particularly to the usual risks faced by a
global pharmaceutical company, including the impact of the prices for
products and raw materials, medication safety, changes in exchange
rates, government regulations, employee relations, taxes, political
instability and terrorism as well as the results of independent
demands and governmental inquiries that affect the affairs of the
company. All forward-looking statements contained in this release
hold true as of the date of publication. They do not represent any
guarantee of future performance. Actual events and developments could
differ materially from the forward-looking statements that are
explicitly expressed or implied in these statements. DAIICHI SANKYO
Co., Ltd. assume no responsibility for the updating of such
forward-looking statements about future developments of the sector,
legal and business conditions and the company.

Contact  Christina Werthner (Europe)  Daiichi Sankyo Europe GmbH  
Head of Corp. Communications  +49-(89)-7808442  
[email protected]

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

print